Anti-retroviral therapeutic effect and factors influencing drug resistance in HIV/AIDS patients in Huaihua city
YU Hong-ying1, LI Yong-zhong1, WEI Xue-feng2, LIU Li-ya3, XIE Zhi-bing1, WANG Pei1
1. The First People’s Hospital of Huaihua City, Huaihua, Hunan 418000, China; 2. Huaihua Municipal Center for Disease Control and Prevention, Huaihua, Hunan 418000, China; 3. School of Laboratory Medicine, Hunan University of Medicine, Huaihua, Hunan 418000, China
Abstract：Objective To investigate the therapeutic effect and drug resistance of HIV/AIDS patients with highly active anti-retroviral therapy (HAART) in Huaihua city, and to analyze the related factors affecting drug resistance. Methods CD4+ T-lymphocyte and viral load were detected in 367 HIV/AIDS patients treated with antiviral therapy for more than one year in the AIDS clinic and wards of the First People’s Hospital of Huaihua City and aged above 18 years. We performed HIV drug resistant genotype test in the samples with viral load greater than 1,000 copies/ml, and further statistically analyzed the level of CD4+ T-lymphocyte before the treatment, the grade of treatment compliance and the proportion of using anti-tuberculosis drugs during HAART treatment based on grouping. Results Among the patients in the study, 86.65% used first-line therapy, 92.37% achieved virological inhibition, 7.63% had virological failure and 13.89% had CD4+ T-lymphocyte less than 200 cells/μl. 18 patients developed drug resistance, and the incidence rate of drug resistance was 4.90%. There were statistically significant differences in the level of CD4+ T-lymphocyte before the treatment, the grade of treatment compliance and the proportion of using anti-tuberculosis drugs during HAART treatment between the drug-resistant group and the non-drug-resistant control group. Conclusions The overall curative efficacy of patients receiving anti-retroviral therapy in Huaihua city was remarkable. A few patients developed drug resistance, and there was a correlation between their drug resistance and the level of CD4+ T-lymphocyte before the treatment, the grade of treatment compliance, using anti-tuberculosis drugs during HAART treatment.
[1] Anglemyer A, Rutherford GW, Easterbrook PJ, et al. Early initiation of antiretroviral therapy in HIV-infected adults and adolescents :a systematic review[J].AIDS, 2014,28 Suppl 2:S105-118. [2] Snoeck J, Kantor R, Shafer RW, et a1.Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent[J].Antimicrob Agents Chemother,2006,50(2):694-701. [3] 王维维,奚迪,袁向亮,等.不同流式细胞分析仪检测淋巴细胞亚群的比较研究[J].中华检验医学杂志,2016,39(5):361-365. [4] Prieto-Hinojosa A, Knight A, Compton C, et a1. Reduced thymic output in elite athletes[J].Brain Behav lmmun,2014,39:75-79. [5] 中华医学会感染病学分会艾滋病丙型肝炎学组,中国疾病预防控制中心.中国艾滋病诊疗指南(2018版)[J].中华传染病杂志,2018,36(12):705-724. [6] 覃碧云,贺健梅,邹潇白,等.湖南省252例艾滋病患者抗病毒治疗效果及耐药分析[J].实用预防医学,2012,19(7):964-967. [7] 陈琳,潘晓红,杨介者,等.浙江省273名抗病毒治疗患者HIV-1毒株耐药性及其影响因素研究[J].疾病监测,2010,25(11):869-873. [8] Nannini EC, Han X, O'Brien WA, et al. Genotypic HIV-1 drug resistance testing in antiretroviral-naive subjects in Houston, Texas[J]. J Acquir Immune Defic Syndr,2002,29(3):317-319. [9] Xing H, Wang X, Liao L, et al. Incidence and associated factors of HIV drug resistance in Chinese HIV-infected patients receiving antiretroviral treatment[J].PLoS One,2013, 8(4):e62408. [10] 张曼,胡清海,程华,等.中国部分地区人免疫缺陷病毒耐药及其影响因素分析[J].中国实用内科杂志,2007,27(12):942-944. [11] World Health Organization. Tuberculosis fact sheet[EB/OL].(2017-02-15)[2019-06-20].http:// www.who.int/mediacentre/factsheets/fs104/en/. [12] 中华医学会感染病学分会艾滋病学组,中华医学会热带病与寄生虫学分会艾滋病学组.HIV合并结核分枝杆菌感染诊治专家共识[J].中华临床感染病杂志,2017,10(2):81-90. [13] Marzolini C, Telenti A, Decosterd LA, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients[J].AIDS,2001,15(1):71-75. [14] 张超, 付钰淋, 李华, 等. 陕西省HIV/AIDS患者接受抗病毒治疗后病毒载量结果及其影响因素分析[J].实用预防医学,2019,26(4):397-399.
2020, Vol. 27 
